<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01156220</url>
  </required_header>
  <id_info>
    <org_study_id>IPT0901</org_study_id>
    <nct_id>NCT01156220</nct_id>
  </id_info>
  <brief_title>Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers</brief_title>
  <official_title>Investigation of Gender Specificity of the Effects of Furosemide in Healthy Female and Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the gender specificity of the effects of furosemide in female and male
      volunteers will be investigated. The healthy volunteers receive 1. furosemide and 2.
      aminohippurate sodium &quot;PAH&quot; as single dose. The main objective is gender-specific comparison
      of the pharmacokinetic parameters of furosemide in relation to the effect of furosemide
      (urinary excretion). Secondary objectives are the gender-specific comparison of renal and
      systemic PAH clearance with the clearance of furosemide and the influence of various genetic
      polymorphisms on the variability of furosemide pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic parameter of furosemide (AUC-24)</measure>
    <time_frame>day 1 or day 2</time_frame>
    <description>Gender-specific comparison of the pharmacokinetic parameters of furosemide (AUC-24). The sample size calculation for this study was conducted with respect to the expected gender difference in the AUC24 of furosemide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacodynamic parameter of furosemide (Sodium excretion in the urine)</measure>
    <time_frame>day 1 or day 2</time_frame>
    <description>Gender-specific comparison of effect of furosemide on urinary excretion (sodium)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic parameters</measure>
    <time_frame>day 1</time_frame>
    <description>Influence of various genetic polymorphism (OAT1, OAT 4, OATP1B1, NKCC2, NCC, ENaC) on the variability of pharmacokinetic of furosemide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic of aminohippuric acid</measure>
    <time_frame>day 1 or day 2</time_frame>
    <description>gender-specific comparison of renal and systemic PAH clearance with the clearance of furosemide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other pharmacokinetic parameter of furosemide</measure>
    <time_frame>day 1 or day 2</time_frame>
    <description>Gender-specific comparison of the other pharmacokinetic parameters of furosemide (Cmax, tmax, t½, CLoral, CLren)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other pharmacodynamic parameter of furosemide</measure>
    <time_frame>day 1 or day 2</time_frame>
    <description>Gender-specific comparison of effect of furosemide on urinary excretion (chloride, potassium, uric acid, calcium, magnesium, creatinine)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Male and Female Volunteers</condition>
  <arm_group>
    <arm_group_label>female</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The healthy female volunteers receive furosemide and aminohippurate sodium &quot;PAH&quot; as single dose randomised on day 1 or day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>male</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The healthy male volunteers receive furosemide and aminohippurate sodium &quot;PAH&quot; as single dose randomised on day 1 or day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Injection, 40 mg, single dose over 5 min</description>
    <arm_group_label>female</arm_group_label>
    <arm_group_label>male</arm_group_label>
    <other_name>ATC code: C03CA01</other_name>
    <other_name>Product name: Lasix 40 mg Injektionslösung</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aminohippurate sodium</intervention_name>
    <description>Injection, 500 mg, single dose over 5 min</description>
    <arm_group_label>female</arm_group_label>
    <arm_group_label>male</arm_group_label>
    <other_name>ATC code: V04CH30,</other_name>
    <other_name>Product name: Aminohipppurate Sodium &quot;PAH&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer for medical history and physical examination findings

          -  18 years, &lt;40 years

          -  Written informed consent is given

          -  No clinically relevant changes in laboratory parameters

          -  Inconspicuous current ECG

          -  taking medication under a different drug trial within the last 30 days

        Exclusion Criteria:

          -  concomitant medication at study days or a week before

          -  allergies or known hypersensitivity reactions to furosemide or aminohippurate sodium

          -  decreased creatinine clearance by Cockcroft-Gault (&lt;100 ml / min)

          -  current drug abuses

          -  opiate addiction within the last 10 years

          -  smoking within the last year

          -  pregnancy and 6 months postpartum, lactation

          -  deprivation of legal capacity

          -  Cooperation inability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Eschenhagen, Prof.Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Universitätsklinikum Hamburg-Eppendorf Martinistr. 52 20246 Hamburg GERMANY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Werner, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Universitätsklinikum Hamburg-Eppendorf Martinistr. 52 20246 Hamburg GERMANY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrike Werner, PD Dr.</last_name>
    <phone>040-741055058</phone>
    <email>uwerner@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Center North</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alen Jambrecina, Dr. med.</last_name>
      <phone>+49 40 7410 51603</phone>
      <email>a.jambrecina@uke.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Thomas Eschenhagen</name_title>
    <organization>Institut für Pharmakologie und Toxikologie</organization>
  </responsible_party>
  <keyword>gender, diuretics, furosemide, aminohippuric acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

